These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1436301)

  • 1. Marked eosinophilia induced by nafamostat mesilate, an anticoagulant in a hemodialysis patient.
    Nakanishi K; Kaneko T; Yano F; Horio M; Kawagoe H; Fujii M; Kashiwai K
    Nephron; 1992; 62(1):97-9. PubMed ID: 1436301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialysis patient.
    Yamazato M; Mano R; Oshiro-Chinen S; Tomiyama N; Sakima A; Ishida A; Tana T; Tozawa M; Muratani H; Iseki K; Takishita S
    Intern Med; 2002 Oct; 41(10):864-6. PubMed ID: 12413011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient.
    Maruyama H; Miyakawa Y; Gejyo F; Arakawa M
    Nephron; 1996; 74(2):468-9. PubMed ID: 8893192
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adsorption of Nafamostat Mesilate on AN69ST Membranes: A Single-Center Retrospective and In Vitro Study.
    Nakamura Y; Hara S; Hatomoto H; Yamasaki S; Nakano T; Miyazaki M; Matsumoto N; Irie Y; Ishikura H
    Ther Apher Dial; 2017 Dec; 21(6):620-627. PubMed ID: 28960755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can nafamostat mesilate be used for temporary management of hemodialysis in a patient with heparin-induced thrombocytopenia (HIT)?
    Matsuo T; Matsuo M; Ouga-Maruyama S
    Thromb Haemost; 2001 Oct; 86(4):1115-6. PubMed ID: 11686333
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustained severe intestinal edema after nafamostat mesilate-associated anaphylactic reaction during hemodialysis.
    Shindo M; Ookawara S; Kitano T; Ishii H; Miyazawa H; Ito K; Ueda Y; Hirai K; Hoshino T; Morishita Y
    Nefrologia (Engl Ed); 2019; 39(2):202-204. PubMed ID: 30220495
    [No Abstract]   [Full Text] [Related]  

  • 9. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage.
    Yang JW; Han BG; Kim BR; Lee YH; Kim YS; Yu JM; Choi SO
    Ren Fail; 2009; 31(8):668-75. PubMed ID: 19814633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
    Lee YK; Lee HW; Choi KH; Kim BS
    PLoS One; 2014; 9(10):e108737. PubMed ID: 25302581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant.
    Nagase K; Fukunaga K; Ohnishi K; Kusaka T; Matoba Y; Sawada K
    Ther Apher Dial; 2004 Feb; 8(1):45-51. PubMed ID: 15128019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
    Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
    Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient.
    Takahashi H; Muto S; Nakazawa E; Yanagiba S; Masunaga Y; Miyata Y; Tamba K; Kusano E; Matsuo M; Matsuo T; Asano Y
    Clin Nephrol; 2003 Jun; 59(6):458-62. PubMed ID: 12834179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional mechanisms of nafamostat mesilate-associated hyperkalaemia.
    Ookawara S; Tabei K; Sakurai T; Sakairi Y; Furuya H; Asano Y
    Eur J Clin Pharmacol; 1996; 51(2):149-51. PubMed ID: 8911880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient.
    Higuchi N; Yamazaki H; Kikuchi H; Gejyo F
    Nephron; 2000 Nov; 86(3):400-1. PubMed ID: 11096324
    [No Abstract]   [Full Text] [Related]  

  • 17. Nafamostat mesilate is not appropriate as an anticoagulant during continuous renal replacement therapy in dogs.
    Shimokawa Miyama T; Yoshioka C; Minami K; Okawa T; Hiraoka H; Itamoto K; Mizuno T; Okuda M
    J Vet Med Sci; 2010 Mar; 72(3):363-7. PubMed ID: 19959883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an anticoagulant (heparin versus nafamostat mesilate) on the extrinsic coagulation pathway in chronic hemodialysis.
    Matsuo T; Matsuo M; Kario K; Koide M
    Blood Coagul Fibrinolysis; 1998 Jun; 9(4):391-3. PubMed ID: 9690813
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiac arrest caused by nafamostat mesilate.
    Kim HS; Lee KE; Oh JH; Jung CS; Choi D; Kim Y; Jeon JS; Han DC; Noh H
    Kidney Res Clin Pract; 2016 Sep; 35(3):187-9. PubMed ID: 27668164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
    Han SJ; Kim HS; Kim KI; Whang SM; Hong KS; Lee WK; Lee SH
    J Korean Med Sci; 2011 Jul; 26(7):945-50. PubMed ID: 21738350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.